S-1 plus cisplatin

DRUG4 trials

Sponsors

Sun Yat-sen University, Asan Medical Center, Kyungpook National University Hospital, Taiho Pharmaceutical Co., Ltd.

Conditions

Gastric CancerMetastatic Biliary Cancer

Phase 2

Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma

CompletedNCT01375972

Asan Medical CenterMetastatic Biliary Cancer

Start: 2008-03-31End: 2011-08-31Updated: 2011-12-06

S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer

Kyungpook National University HospitalGastric Cancer

Start: 2011-09-30End: 2016-09-30Target: 218Updated: 2012-01-05

Phase 3

Trial of S-1 Plus Cisplatin in Gastric Cancer

Sun Yat-sen UniversityGastric Cancer

Start: 2008-09-30End: 2011-12-31Target: 270Updated: 2011-07-25

Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

CompletedNCT02322593

Taiho Pharmaceutical Co., Ltd.Gastric Cancer

Start: 2014-12-31End: 2020-05-31Updated: 2021-12-20

Related Papers

Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

BMC Cancer2021-07-1610 citations

S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.

2020-07-1668 citations

Feasibility and pathological response of TAS-118 + oxaliplatin as perioperative chemotherapy for patients with locally advanced gastric cancer (APOLLO-11).

Journal of Clinical Oncology2020-02-01

Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy

BMC Cancer2018-01-082 citations

S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study

Oncotarget2015-10-0222 citations